Subscribe
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Ovarian Overview
Ovarian Cancer
Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care
Ovarian Cancer
Web Exclusives
The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum.
Read More ›
NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer
Ovarian Cancer
Web Exclusives
In the treatment of patients with platinum-sensitive, recurrent ovarian cancer, a lower starting dose of niraparib in patients with a low body weight (77 kg) or low platelet count (150,000/μL) had similar efficacy as the fixed 300-mg starting dose versus placebo on the end point of progression-free survival, confirming a previous observation.
Read More ›
Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer
Ovarian Cancer
Web Exclusives
A review of the National Cancer Database reveals that use of neoadjuvant chemotherapy for advanced epithelial ovarian cancer increased markedly between 2004 and 2016. At the same time, median survival improved by more than 6 months. Study authors found no association between the 2 trends.
Read More ›
Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months
Ovarian Cancer
Web Exclusives
Data from a real-world setting show that a platinum-free interval >12 months was associated with the best outcomes after progression on PARP inhibitor maintenance in patients with high-grade serous ovarian cancer.
Read More ›
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Ovarian Cancer
Web Exclusives
ASCO guidelines cite significant improvement in progression-free survival when PARP inhibitors are used as maintenance therapy or in the setting of recurrent disease in women with advanced ovarian cancer who have responded to platinum-based chemotherapy in the first line.
Read More ›
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Ovarian Cancer
Web Exclusives
In an analysis of the phase 3 PRIMA study, niraparib monotherapy as first-line maintenance after platinum-based chemotherapy improved progression-free survival in women with newly diagnosed advanced ovarian cancer regardless of
BRCA
mutation status or homologous recombination status (deficient or proficient).
Read More ›
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Ovarian Cancer
Web Exclusives
In the PAOLA-1 study, women with advanced ovarian cancer, regardless of
BRCA
mutation status, experienced a 40% reduction in the risk for disease progression or death when randomized to olaparib plus bevacizumab compared with placebo and bevacizumab. The reduction in risk with olaparib was greatest in patients whose tumors were homologous recombination deficient.
Read More ›
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Ovarian Cancer
Web Exclusives
In a 4-arm randomized study, providing telephone genetic counseling only to those women who have a pathogenic mutation or who request the counseling is noninferior to mandatory pre- and posttest counseling, which may represent a new paradigm for genetic testing.
Read More ›
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Ovarian Cancer
Web Exclusives
In the phase 2 OVARIO study, median progression-free survival has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities.
Read More ›
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Ovarian Cancer
Web Exclusives
An all-oral regimen in women with recurrent platinum-sensitive ovarian cancer did not show superiority to platinum-based regimens on the outcome of progression-free survival.
Read More ›
Page 8 of 13
3
4
5
6
7
8
9
10
11
12
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION